<?xml version='1.0' encoding='utf-8'?>
<document id="19007592"><sentence text="Calcium-channel blockers reduce the antiplatelet effect of clopidogrel."><entity charOffset="0-7" id="DDI-PubMed.19007592.s1.e0" text="Calcium" /><entity charOffset="59-70" id="DDI-PubMed.19007592.s1.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.19007592.s1.e0" e2="DDI-PubMed.19007592.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19007592.s1.e0" e2="DDI-PubMed.19007592.s1.e1" /></sentence><sentence text="Because of the known CYP3A4 inhibition by calcium-channel blockers (CCBs), we hypothesized that there might be a drug-drug interaction between clopidogrel and dihydropyridines in patients with coronary artery disease"><entity charOffset="42-49" id="DDI-PubMed.19007592.s2.e0" text="calcium" /><entity charOffset="143-154" id="DDI-PubMed.19007592.s2.e1" text="clopidogrel" /><entity charOffset="159-175" id="DDI-PubMed.19007592.s2.e2" text="dihydropyridines" /><pair ddi="false" e1="DDI-PubMed.19007592.s2.e0" e2="DDI-PubMed.19007592.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19007592.s2.e0" e2="DDI-PubMed.19007592.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19007592.s2.e0" e2="DDI-PubMed.19007592.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19007592.s2.e1" e2="DDI-PubMed.19007592.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19007592.s2.e1" e2="DDI-PubMed.19007592.s2.e2" /></sentence><sentence text="" /><sentence text="Clopidogrel is activated by CYP3A4, which also metabolizes CCBs of the dihydropyridine class"><entity charOffset="0-11" id="DDI-PubMed.19007592.s4.e0" text="Clopidogrel" /><entity charOffset="71-86" id="DDI-PubMed.19007592.s4.e1" text="dihydropyridine" /><pair ddi="false" e1="DDI-PubMed.19007592.s4.e0" e2="DDI-PubMed.19007592.s4.e0" /><pair ddi="false" e1="DDI-PubMed.19007592.s4.e0" e2="DDI-PubMed.19007592.s4.e1" /></sentence><sentence text="" /><sentence text="Responsiveness to clopidogrel was assessed by the vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay and aggregometry in 200 patients with coronary artery disease undergoing percutaneous coronary intervention"><entity charOffset="18-29" id="DDI-PubMed.19007592.s6.e0" text="clopidogrel" /></sentence><sentence text="" /><sentence text="The platelet reactivity index (PRI) (in the VASP assay, normal range 69% to 100%) was higher in patients receiving both clopidogrel and CCBs (61%) as compared with patients receiving clopidogrel without CCBs (48%)"><entity charOffset="120-131" id="DDI-PubMed.19007592.s8.e0" text="clopidogrel" /><entity charOffset="136-140" id="DDI-PubMed.19007592.s8.e1" text="CCBs" /><entity charOffset="183-194" id="DDI-PubMed.19007592.s8.e2" text="clopidogrel" /><entity charOffset="203-213" id="DDI-PubMed.19007592.s8.e3" text="CCBs" /><pair ddi="false" e1="DDI-PubMed.19007592.s8.e0" e2="DDI-PubMed.19007592.s8.e0" /><pair ddi="false" e1="DDI-PubMed.19007592.s8.e0" e2="DDI-PubMed.19007592.s8.e1" /><pair ddi="false" e1="DDI-PubMed.19007592.s8.e0" e2="DDI-PubMed.19007592.s8.e2" /><pair ddi="false" e1="DDI-PubMed.19007592.s8.e0" e2="DDI-PubMed.19007592.s8.e3" /><pair ddi="false" e1="DDI-PubMed.19007592.s8.e1" e2="DDI-PubMed.19007592.s8.e1" /><pair ddi="false" e1="DDI-PubMed.19007592.s8.e1" e2="DDI-PubMed.19007592.s8.e2" /><pair ddi="false" e1="DDI-PubMed.19007592.s8.e1" e2="DDI-PubMed.19007592.s8.e3" /><pair ddi="false" e1="DDI-PubMed.19007592.s8.e2" e2="DDI-PubMed.19007592.s8.e2" /><pair ddi="false" e1="DDI-PubMed.19007592.s8.e2" e2="DDI-PubMed.19007592.s8.e3" /></sentence><sentence text=" The absolute difference was 13% (95% confidence interval: 6% to 20%; p = 0" /><sentence text="001), and the relative difference approached 21%" /><sentence text=" A decreased platelet inhibition by clopidogrel (PRI &gt;69%) was seen in 40% of patients with concomitant CCB treatment and in 20% of patients without concomitant treatment (chi-square test, p = 0"><entity charOffset="36-47" id="DDI-PubMed.19007592.s11.e0" text="clopidogrel" /></sentence><sentence text="008)" /><sentence text=" Intake of CCB remained an independent predictor of reduced platelet inhibition by clopidogrel after adjustment for cardiovascular risk factors"><entity charOffset="83-94" id="DDI-PubMed.19007592.s13.e0" text="clopidogrel" /></sentence><sentence text=" Adenosine diphosphate-induced platelet aggregation was 30% higher in patients on concomitant CCB treatment compared with patients without CCBs (p = 0"><entity charOffset="1-22" id="DDI-PubMed.19007592.s14.e0" text="Adenosine diphosphate" /><entity charOffset="139-159" id="DDI-PubMed.19007592.s14.e1" text="CCBs" /><pair ddi="false" e1="DDI-PubMed.19007592.s14.e0" e2="DDI-PubMed.19007592.s14.e0" /><pair ddi="false" e1="DDI-PubMed.19007592.s14.e0" e2="DDI-PubMed.19007592.s14.e1" /></sentence><sentence text="046)" /><sentence text=" Moreover, intake of CCBs was associated with adverse clinical outcome"><entity charOffset="21-24" id="DDI-PubMed.19007592.s16.e0" text="CCBs" /></sentence><sentence text=" In vitro incubation with CCBs (nimodipine, verapamil, amlodipine, and diltiazem) did not alter the PRI or the adenosine diphosphate-induced platelet aggregation of patients taking clopidogrel"><entity charOffset="26-30" id="DDI-PubMed.19007592.s17.e0" text="CCBs" /><entity charOffset="32-42" id="DDI-PubMed.19007592.s17.e1" text="nimodipine" /><entity charOffset="44-53" id="DDI-PubMed.19007592.s17.e2" text="verapamil" /><entity charOffset="55-65" id="DDI-PubMed.19007592.s17.e3" text="amlodipine" /><entity charOffset="71-80" id="DDI-PubMed.19007592.s17.e4" text="diltiazem" /><entity charOffset="111-132" id="DDI-PubMed.19007592.s17.e5" text="adenosine diphosphate" /><entity charOffset="181-192" id="DDI-PubMed.19007592.s17.e6" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e0" e2="DDI-PubMed.19007592.s17.e0" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e0" e2="DDI-PubMed.19007592.s17.e1" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e0" e2="DDI-PubMed.19007592.s17.e2" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e0" e2="DDI-PubMed.19007592.s17.e3" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e0" e2="DDI-PubMed.19007592.s17.e4" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e0" e2="DDI-PubMed.19007592.s17.e5" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e0" e2="DDI-PubMed.19007592.s17.e6" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e1" e2="DDI-PubMed.19007592.s17.e1" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e1" e2="DDI-PubMed.19007592.s17.e2" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e1" e2="DDI-PubMed.19007592.s17.e3" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e1" e2="DDI-PubMed.19007592.s17.e4" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e1" e2="DDI-PubMed.19007592.s17.e5" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e1" e2="DDI-PubMed.19007592.s17.e6" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e2" e2="DDI-PubMed.19007592.s17.e2" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e2" e2="DDI-PubMed.19007592.s17.e3" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e2" e2="DDI-PubMed.19007592.s17.e4" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e2" e2="DDI-PubMed.19007592.s17.e5" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e2" e2="DDI-PubMed.19007592.s17.e6" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e3" e2="DDI-PubMed.19007592.s17.e3" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e3" e2="DDI-PubMed.19007592.s17.e4" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e3" e2="DDI-PubMed.19007592.s17.e5" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e3" e2="DDI-PubMed.19007592.s17.e6" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e4" e2="DDI-PubMed.19007592.s17.e4" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e4" e2="DDI-PubMed.19007592.s17.e5" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e4" e2="DDI-PubMed.19007592.s17.e6" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e5" e2="DDI-PubMed.19007592.s17.e5" /><pair ddi="false" e1="DDI-PubMed.19007592.s17.e5" e2="DDI-PubMed.19007592.s17.e6" /></sentence><sentence text=" This finding indicates that the negative effect occurs in vivo, conceivably at the level of the CYP3A4 cytochrome" /><sentence text="" /><sentence text="Coadministration of CCBs is associated with decreased platelet inhibition by clopidogrel"><entity charOffset="77-88" id="DDI-PubMed.19007592.s20.e0" text="clopidogrel" /><entity charOffset="20-30" id="DDI-PubMed.19007592.s20.e1" text="CCBs" /><pair ddi="false" e1="DDI-PubMed.19007592.s20.e1" e2="DDI-PubMed.19007592.s20.e1" /><pair ddi="false" e1="DDI-PubMed.19007592.s20.e1" e2="DDI-PubMed.19007592.s20.e0" /></sentence><sentence text="" /></document>